Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Hintergrund zur Entstehung des Buches Kapitel lesen Erstes Kapitel lesen

2020 | OriginalPaper | Buchkapitel

9. Therapeutische Strategien bei Alkohol- und Tabakabhängigkeit

verfasst von : Otto-Michael Lesch, Henriette Walter, Samuel Pombo, Victor Hesselbrock, Michie Hesselbrock

Erschienen in: Alkohol und Tabak

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Antwort der Gesellschaft auf die alte Frage – was einen Suchtkranken dazu verleitet Alkohol, Tabak oder Drogen (erneu) zu konsumieren – auch nachdem ihr Leben bereits signifikant von diesen geschädigt wurde – führt oft zu einer allzu simplen Antwort: Schwacher Wille!
Literatur
Ait-Daoud N, Lynch WJ, Penberthy JK, Breland AB, Marzani-Nissen GR, Johnson BA (2006) Treating smoking dependence in depressed alcoholics. Alcohol Res Health 29(3):213–220PubMedPubMedCentral
Alkam T, Mamiya T, Kimura N, Yoshida A, Kihara D, Tsunoda Y, Aoyama Y, Hiramatsu M, Kim HC, Nabeshima T (2017) Prenatalnicotineexposure decreases the release of dopamine in the medial frontal cortex and induces atomoxetine-responsive neurobehavioral deficits in mice. Psychopharmacology 234(12):1853–1869. https://​doi.​org/​10.​1007/​s00213-017-4591-zCrossRefPubMed
Anthenelli R. (2004) Smoking cessation in smokers motivated to quit. Presented at American college of cardiology scientific sessions, 7–10 March 2004, New Orleans
Anthenelli RM, Smith TL, Craig CE, Tabakoff B, Schuckit MA (1995) Platelet monoamine oxidase activity levels in subgroups of alcoholics: diagnostic, temporal, and clinical correlates. Biol Psychiatry 38:361–368PubMed
Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE (2016) Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 387(10037):2507–2520PubMed
Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A, COMBINE Study Research Group (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295(17):2003–2017PubMed
Aubin HJ, Luquiens A, Berlin I (2014) Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. Br J Clin Pharmacol 77:324–336PubMedPubMedCentral
Bekiroglu K, Russell MA, Lagoa CM, Lanza ST, Piper ME (2017) Evaluating the effect of smoking cessation treatment on a complex dynamical system. Drug Alcohol Depend 1(180):215–222
Benkelfat C, Murphy D, Hill J, George DT, Nutt D, Linnoila M (1991) Ethanol like properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients. Arch Gen Psychiatry 48:383PubMed
Benowitz NL, Porchet H, Sheiner L, Jacob P III (1988) Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 44:23–28PubMed
Beresford TP, Arciniegas DB, Alfers J, Clapp L, Martin B, Du Y, Liu D, Shen D, Davatzikos C (2006a) Hippocampus volume loss due to chronic heavy drinking. Alcohol Clin Exp Res 30(11):1866–1870PubMed
Beresford TP, Arciniegas DB, Alfers J, Clapp L, Martin B, Beresford HF, Du Y, Liu D, Shen D, Davatzikos C, Laudenslager ML (2006b) Hypercortisolism in alcohol dependence and its relation to hippocampal volume loss. J Stud Alcohol 67(6):861–867PubMed
Berger IK, Miller SD (2006) Kurzzeittherapie bei Alkoholproblemen. Ein lösungsorientierter Ansatz (engl.: Working with the problem drinker) Carl Auer Verlag, Heidelberg
Besson J, Aeby F, Kasas A, Lehert P, Potgieter A (1998) Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 22(3):573–579PubMed
Blanc M, Daeppen JB (2005) Does disulfiram still have a role in alcoholism treatment? Rev Med Suisse 1(26):1728–1733PubMed
Bolt DM, Piper ME, Theobald WE, Baker TB (2012) Why two smoking cessation agents work better than one: role of craving suppression. J Consult Clin Psychol 80:54–65PubMed
Bonte W (1987) Begleitstoffe alkoholischer Getränke. Max Schmidt-Römhild, Lübeck
Brady KT, Myrick H, Henderson S, Coffey SF (2002) The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend 67(3):323–330PubMed
Brasser SM, Castro N, Feretic B (2015) Alcohol sensory processing and its relevance for ingestion. Physiol Behav 148:65–70PubMed
van den Brinck W, Sorensen P, Torup L, Mann K, Gual A, SENSE Study Group (2014) Long-term efficacy,tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1 – year, randomized controlled study. J Psychopharmacol 28:733–744
van den Brink W, Addolorato G, Aubin HJ, Benyamina A, Caputo F, Dematteis M, Gual A, Lesch OM, Mann K, Maremmani I, Nutt D, Paille F, Perney P, Rehm J, Reynaud M, Simon N, Söderpalm B, Sommer WH, Walter H, Spanagel R (2018) Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. Addict Biol 23(4):969–986PubMed
Brody AL, Mandelkern MA, London ED, Olmstead RE, Farahi J, Scheibal D, Jou J, Allen V, Tiongson E, Chefer SI, Koren AO, Mukhin AG (2006) Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 63(8):907–915PubMedPubMedCentral
Buchhalter AR, Fant RV, Henningfield JE (2008) Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs 68(8):1067–1088. ReviewPubMed
Buydens-Branchey L, Branchey MH, Noumair D, Lieber CS (1989) Age of alcolism onset. II: relationship to susceptibility to serotonin precursor availibility. Arch Gen Psychiatry 46:231–236PubMed
Cahill K, Ussher M (2007) Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev (3):CD005353
Cahill K, Stead LF, Lancaster T (2007) Nicotine receptor partial agonists for smoking cessation (review). Cochrane Libr 1:1–25
Caputo F, Addolorato G, Lorenzini F, Domenicali M, Greco G, del RE A, Gasbarrini G, Stefanini GF, Bernardi M (2003) Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. Drug Alcohol Depend 70(1):85–91PubMed
Caputo F, Addolorato G, Trevisani F, Bernardi M (2005) Gamma-hydroxybutyrate as a treatment for alcoholism. Lancet 366(9490):981–982PubMed
Caputo F, Vignoli T, Maremmani I, Bernardi M, Zoli G (2009) Gamma hydroxibutyric acid (GHB ) for the treatment of alcohol dependence: a review. Int J Environ Res Public Health 6(6):1917–1929PubMedPubMedCentral
Caputo F, Del Re A, Brambilla R, Grignaschi A, Vignoli T, Vigna-Taglianti F, Addolorato G, Zoli G, Cibin M, Bernardi M (2014a) Sodium oxybate in maintaining alcohol abstinence in alcohol abstinence in alcoholic patients according to Lesch typology a pilot study. J Psychopharmacol 28(1):23–30PubMed
Caputo F, Skala K, Mirijello A, Ferrulli A, Walter H, Lesch O, Addolorato G (2014b) Sodium Oxybate in the treatment of alcohol withdrawal syndrome: a randomized double – blind comparative study versus oxacepam, The GATE 1 trial. CNS Drugs 28(8):743–752PubMed
Cardoso RA, Brozowski SJ, Chavez-Noriega LE, Harpold M, Valenzuela CF, Harris RA (1999) Effects of ethanol on recombinant human neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Pharmacol Exp Ther 289(2):774–780PubMed
Caputo F, Vignoli T, Grignoschi A, Cibin M, Adolorato G, Bernardi M (2014) Pharmacological management of alcohol dependence: from mono-therapy to pharmacogenetics and beyond. Eur. Neuropsychopharmacol 2014 Feb, 24(2):181–91
Caspi A, Moffitt TE (2006) Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci 7(7):583–590PubMed
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301(5631):386–389PubMed
Cheer JF, Wassum KM, Sombers LA, Heien ML, Ariansen JL, Aragona BJ, Phillips PE, Wightman RM (2007) Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci 27(4):791–795PubMedPubMedCentral
Chick J (1995) Acamprosate as an aid in the treatment of alcoholism. Alcohol Alcohol 30(6):785–787PubMed
Chick J (2004) Disulfiram: cautions on liver function; how to supervise. Addiction 99(1):25PubMed
Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B (2000) A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 35(6):587–593PubMed
Cloninger CR, Sigvardsson S, Gilligan SB, von Knorring AL, Reich T, Bohman M (1988) Genetic heterogeneity and the classification of alcoholism. Adv Alcohol Subst Abuse 7(3–4):3–16PubMed
Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O’Neill BT (2005) Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48(10):3474–3477PubMed
Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P (2002) SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13:451–463PubMed
Cohen C, Kodas E, Griebel G (2005) CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav 81(2):387–395PubMed
Colombo G, Agabio R, Fa M, Guano L, Lobina C, Loche A, Reali R, Gessa GL (1998) Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716. Alcohol Alcohol 33(2):126–130PubMed
Colombo G, Serra S, Vacca G, Carai MA, Gessa GL (2005) Endocannabinoid system and alcohol addiction: pharmacological studies. Pharmacol Biochem Behav 81(2):369–380PubMed
Colombo G, Orrù A, Lai P, Cabras C, Maccioni P, Rubio M, Gessa GL, Carai MA (2007) The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence. Mol Neurobiol 36(1):102–112PubMed
Cooper ML, Frone M, Russell M, Mudar P (1995) Drinking to regulate positive and negative emotions: a motivational model of alcohol use. J Pers Soc Psychol 69:990–1005PubMed
Cornelius JR, Salloum IM, Mezzich J, Cornelius MD, Fabrega H, Ehler JG, Ulrich RF, Thase ME, Mann JJ (1995) Disproportionate suicidality in patients with comorbid major depression and alcoholism. Am J Psychiatr 152:358–364PubMed
Covey LS, Glassman AH, Jiang H, Fried J, Masmela J, Loduca C, Petkova E, Rodriguez K (2007) A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. Addiction 102(8):1292–1302PubMed
Coyle JT (2006) Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms. Neurotox Res 10(3-4):221–233PubMed
Crews FT, Collins MA, Dlugos C, Littleton J, Wilkins L, Neafsey EJ, Pentney R, Snell LD, Tabakoff B, Zou J, Noronha A (2004) Alcohol-induced neurodegeneration: when, where and why? Alcohol Clin Exp Res 28(2):350–364PubMed
Danysz W, Parsons CG, Jirgensons A, Kauss V, Tillner J (2002) Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists. Curr Pharm Des 8(10):835–843PubMed
De Sousa A, De Sousa A (2004) A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence. Alcohol Alcohol 39(6):528–531PubMed
De Witte P, Littleton J, Parot P, Koob G (2005) Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 19(6):517–537PubMed
Deehan GA Jr, Knight CP, Waeiss RA, Engleman EA, Toalston JE, McBride WJ, Hauser SR, Rodd ZA (2016) Peripheral administration of ethanol results in a correlated increase in dopamine and serotonin within the posterior ventral tegmental area. Alcohol Alcohol 51(5):535–540PubMedPubMedCentral
Demir B, Ucar G, Ulug B, Ulusoy S, Sevinc I, Batur S (2002) Platelet monoamine oxidase acitivity in alcoholism subtypes: relationships to personality and executive functions. Alcohol Alcohol 37:597–602PubMed
Després JP, Golay A, Sjöström L (2005) Effects of Rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121–2134PubMed
Deutsche Hauptstelle für Suchtfragen (DHS) (2013a) Alkoholabhängigkeit, Suchtmedizinische Reihe, 4. Aufl. Hamm Deutschland
Deutsche Hauptstelle für Suchtfragen (DHS) (2013b) Tabakabhängigkeit, Suchtmedizinische Reihe, 4. Aufl. Hamm Deutschland
Donoghue K, Elzerbi C, Saunders R, Whittington C, Pilling S, Drummond C (2015) The efficacy of accamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. Addiction 110:920–930PubMed
Ebbert JO, Hughes JR, West RJ, Rennard SI, Russ C, McRae TD, Treadow J, Yu CR, Dutro MP, Park PW (2015) Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA 313(7):687–694PubMedPubMedCentral
Edwards NB, Simmons RC, Rosenthal TL, Hoon PW, Downs JM (1988) Doxepin in the treatment of nicotine withdrawal. Psychomatics 29:203–206
Evans SM, Levin FR, Brooks DJ, Garawi F (2007) A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res 31(5):775–782PubMed
Ferry LH (1999) Non-nicotine pharmacotherapy for smoking cessation. Prim Care 26:653–669PubMed
Fiore M, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, Heyman RB, Jaen CR, Kottke TE, Lando HA, Mecklenberg RE, Mullen PD, Nett LM, Robinson L, Stizer ML, Tommasello AC, Villejo L, Wewers ME (2000) Treating tobacco use and dependence. Clinical practice guideline. US Department of Health and Human Services, Public Health Service, Rockville
Freynhagen R, Backonja M, Schug S, Lyndon G, Parsons B, Watt S, Behar R (2016) Pregabalin for the treatment of drug and alcohol withdrawal symptoms: a comprehensive review. CNS Drugs 30(12):1191–1200. ReviewPubMedPubMedCentral
Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT (1999) Pharmacological treatment of alcohol dependence: a review of the evidence. J Am Med Assoc 281:1318–1325
Garbutt JC, Kranzler HR, O’Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW, Vivitrex Study Group (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293(13):1617–1625PubMed
Gessa GL, Serra S, Vacca G, Carai MA, Colombo G (2005) Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcohol 40(1):46–53PubMed
Glassman AH, Stetner F, Walsh BT, Raizman PS, Fleiss JL, Cooper TB, Covey LS (1988) Heavy smokers, smoking cessation, and clonidine: results of a double-blind, randomized trial. JAMA 259:2863–2866PubMed
Gonzales DH, Rennard SI, Billing CB, Reeves KR (2006) A pooled analysis of varenicline, an alpha4beta2 nicotinic receptor partial agonist versus bupropion for smoking cessation. Presented at society for research on nicotine and toobacco
Hall SM, Reus VI, Munoz RF, Sees KL, Humfleet G, Hartz DT, Frederick S, Triffleman E (1998) Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 55:683–689PubMed
Harro J, Oreland L (2016) The role of MAO in personality and drug use. Prog Neuro-Psychopharmacol Biol Psychiatry 69:101–111
Hashimoto JG, Wiren KM (2008) Neurotoxic consequences of chronic alcohol withdrawal: expression profiling reveals importance of gender over withdrawal severity. Neuropsychopharmacology 33(5):1084–1096PubMed
Heilig M, Koob GF (2007) A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 30(8):399–406PubMedPubMedCentral
Heinz A, Mann K, Weinberger DR, Goldman D (2001) Serotonergic dysfunction, negative mood states, and response to alcohol. Alcohol Clin Exp Res 25:487–495PubMed
Henningfield JE, Fant RV, Gopalan L (1998) Non-nicotine medications for smoking cessation. J Respir Dis 19:33–42
Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML (2005) Pharmacotherapy for nicotine dependence. CA Cancer J Clin 55:281–299PubMed
Hernandez-Avila CA, Song C, Kuo L, Tennen H, Armeli S, Kranzler HR (2006) Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking. Alcohol Clin Exp Res 30(5):860–865PubMed
Hesselbrock VM, Hesselbrock MN (2006) Are there empirically supported and clinically useful subtypes of alcohol dependence? Addiction 101(1):97–103PubMed
Hill EM, Stoltenberg SF, Bullard KH, Li S, Zucker RA, Burmeister M (2002) Antisocial alcoholism and serotonin-related polymorphisms: association tests. Psychiatr Genet 12(3):143–153PubMed
Holm KJ, Spencer CM (2000) Bupropion: a review of its use in the management of smoking cessation. Drugs 59:1007–1024PubMed
Hölter SM, Danysz W, Spanagel R (1996) Evidence for alcohol anti-craving properties of memantine. Eur J Pharmacol 314(3):R1–R2PubMed
Hughes JR, Stead LF, Lancaster T (2004) Antidepressants for smoking cessation. Cochrane Database Syst Rev 18(4): CD000031
Hughes JR, Stead LF, Hartmann-Boyce J, Lancaster T (2014) Antidepressants for smoking cessation. Cochrane Database Syst Rev 8; 2014(1):CD000031
Hwang BH, Wang GM, Wong DT, Lumeng L, Li TK (2000) Norepinephrine uptake sites in the locus coeruleus of rat lines selectively bred for high and low alcohol preference: a quantitative autoradiographic binding study using [3H]-tomoxetine. Alcohol Clin Exp Res 24(5):588–594PubMed
Ipser JC, Wilson D, Akindipe TO, Sager C, Stein DJ (2015) Pharmacotherapy for anxiety and comorbid alcohol use disorders. Cochrane Database Syst Rev 20(1):CD007505
Isgro M, Doran N, Heffner JL, Wong E, Dinh E, Tibbs J, Russell K, Bittner T, Wehrle C, Worley MJ, Anthenelli RM (2017) Type A/Type B alcoholism predicts differential response to topiramate in a smoking cessation trial in dually diagnosed men. J Stud Alcohol Drugs 78(2):232–240PubMedPubMedCentral
Jackson KJ, Muldoon PP, De Biasi M, Damaj MI (2015) New mechanisms and perspectives in nicotine withdrawal. Neuropharmacology 96:223–234PubMed
Jakovljevic M, Jovanovic M, Rancic N, Vyssoki B, Djordjevic N (2014) LAT software induced savings on medical costs of alcohol addicts’care: results from a matched pairs case control study. PLoS One 7:9
Javors M, Tiouririne M, Prihoda T (2000) Platelet serotonin uptake is higher in early onset than in late-onset alcoholics. Alcohol Alcohol 35:390–393PubMed
Joca SR, Ferreira FR, Guimaraes FS (2007) Modulation of stress consequences by hippocampal monoaminergic, glutamatergic and nitrergic neurotransmitter systems. Stress 10(3):227–249PubMed
Johnson BA (2000) Serotonergic agents and alcoholism treatment: rebirth of the subtype concept – a hypothesis. Alcohol Clin Exp Res 24:1597–1601PubMed
Johnson BA (2004a) Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment. CNS Drugs 18(15):1105–1118PubMed
Johnson BA (2004b) Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study. Alcohol Clin Exp Res 28(8):1137–1144PubMed
Johnson BA, Ait-Daoud N (2000) Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology 149:327–344PubMed
Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J (2000a) Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. J Am Med Assoc 284:963–971
Johnson BA, Ait-Daoud N, Prihoda TJ (2000b) Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res 24(5):737–742PubMed
Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ (2003a) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361(9370):1677–1685PubMed
Johnson BA, Ruiz P, Galanter M (2003b) Handbook of clinical alcoholism treatment. Lippincott Williams & Wilkins, Baltimore
Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ (2004) Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 61(9):905–912PubMed
Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Addolorato G, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O’Malley SS, Swift RM (2008) Topiramate for alcoholism advisory board; topiramate for alcoholism study group. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med 168(11):1188–1199PubMed
Jordan CJ, Xi ZX (2018) Discovery and development of varenicline for smoking cessation. Expert Opin Drug Discovery 13(7):671–683
Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685–691PubMed
Kalivas P, Volkow N (2005) The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 162:8
Kampman KM, Pettinati HM, Lynch KG, Whittingham T, Macfadden W, Dackis C, Tirado C, Oslin DW, Sparkman T, O’Brien CP (2007) A double blind, placebo controlled pilot trial of Quetiapine fort he treatment of Type A and Type B alcoholism. J Clin Psychopharmacol 27(4):344–351PubMedPubMedCentral
Kiefer F, Helwig H, Tarnaske T, Otte C, Jahn H, Wiedemann K (2005a) Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. Eur Addict Res 11:83–91PubMed
Kiefer F, Jahn H, Wiedemann K (2005b) A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment. Pharmacopsychiatry 38(4):184–186PubMed
Klemperer EM, Hughes JR, Naud S (2018) Study characteristics influence the efficacy of substance abuse treatments: a meta – analysis of medications for alcohol use disorder. Drug Alcohol Depend 190:229–234PubMed
Klesges RC, Meyers AW, Klesges LM, La Vasque ME (1989) Smoking, body weight, and their effects on smoking behaviour: a comprehensive review of the literature. Psychol Bull 106:204–230PubMed
Klesges RC, Winders SE, Meyers AW, Eck LH, Ward KD, Hultquist CM, Ray JW, Shadish WR (1997) How much weight gain occurs following smoking cessation? A comparison of weight gain using both continuous and point prevalence abstinence. J Consult Clin Psychol 65:286–291PubMed
Koob GF (2014) Neurocircuitry of alcohol addiction: synthesis from animal models. Handb Clin Neurol 125:33–54PubMed
Kosten TR, George TP, Kosten TA (2002) The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs 11(4):491–499. ReviewPubMed
Kotlyar M, Lindgren BR, Vuchetich JP, Le C, Mills AM, Amiot E, Hatsukami DK (2017) Timing of nicotine lozenge administration to minimize trigger induced craving and withdrawal symtoms. Addict Behav 71:18–24PubMedPubMedCentral
Kranzler HR, Burleson JA, DelBoca FK, Babor TF, Korner P, Brown J, Bohn MJ (1994) Buspirone treatment of anxious alcoholics. A placebo controlled trial. Archives of General Psychiatry 51:720–731
Kranzler HR, Burleson JA, Brown J, Babor TF (1996) Fluoxetine treatment seems to reduce the beneficial effects of cognitive behavioral therapy in type B alcoholics. Alcohol Clin Exp Res 20:1534–1541PubMed
Kranzler HR, Lappalainen J, Nellissery M, Gelernter J (2002) Association study of alcoholism subtypes with a functional promoter polymorphism in the serotonin transporter protein gene. Alcohol Clin Exp Res 26(9):1330–1335PubMed
Krishnan-Sarin S, O’Malley SS, Franco N, Cavallo DA, Morean M, Shi J, Pittman B, Krystal JH (2015) N-methyl-D-aspartate receptor antagonism has differential effects on alcohol craving and drinking in heavy drinkers. Alcohol Clin Exp Res 39(2):300–307PubMedPubMedCentral
Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, Gueorguieva R, Petrakis IL, Zvartau EE, Krystal JH (2007) Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res 31(4):604–611PubMed
Krystal JH, Webb E, Cooney NL, Kranzler HR, Charney DS (1994) Specifity of ethanollike effects elicited by serotonergic and noradrenergic mechanisms. Arch Gen Psychiatry 51:898–911PubMed
Laaksonen E, Koski-Jännes A, Salaspuro M, Ahtinen H, Alho H (2008) A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 43(1):53–61PubMed
Le Foll B, Melihan-Cheinin P, Rostoker G, Lagrue G, Working Group of AFSSAPS (2005) Smoking cessation guidelines: evidence-based recommendations of the French health products safety agency. Eur Psychiatry 20(5–6):431–441PubMed
LeMarquand D, Pihl RO, Benkelfat C (1994) Serotonin and alcohol intake, abuse, and dependence: clinical evidence. Biol Psychiatry 36(5):326–337PubMed
Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F (2010) Gamma-hydroxyburate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev (2):CD006266. Review
Lerman C, Niaura R, Collins BN, Wileyto P, Audrain-McGovern J, Pinto A, Hawk L, Epstein LH (2004) Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol Addict Behav 18:362–366PubMed
Lesch OM (1985) Chronischer Alkoholismus – Typen und ihr Verlauf – eine Langzeitstudie. Thieme Copythek, Georg Thieme Verlag, Stuttgart/New York
Lesch OM (2007) Raucherentwöhnung – Tipps zur Prävention und Therapie in der Praxis. Uni-Med Verlag, Wien
Lesch OM, Walter H (1996) Subtypes of alcoholism and their role in therapy. Alcohol Alcohol Suppl 1:63–67
Lesch OM, Lesch E, Dietzel M, Musalek M, Walter H, Zeiler K (1986a) Chronischer Alkoholismus – Alkoholfolgekrankheiten – Faktoren, die die Lebenserwartung beeinflussen. In: Sammelband der Van Swieten Tagung. Verlag der österreichischen Ärztekammer, Wien, S 92–98
Lesch OM, Musalek M, Wessely P, Zeiler K (1986b) Neurologische und psychiatrische Akutmaßnahmen, Abschnitt Psychiatrie. Facultas Universitätsverlag, Wien, S 160–163
Lesch OM, Riegler A, Gutierrez K, Hertling I, Ramskogler K, Semler B, Zoghlami A, Benda N, Walter H (2001) The European Acamprosate trials: conclusions for research and therapy. J Biomed Sci 8(1):89–95PubMed
Lesch OM, Dvorak A, Hertling I, Klingler A, Kunze M, Ramskogler K, Saletu-Zylharz G, Schoberberger R, Walter H (2004) The Austrian multicentre study on smoking: subgroups of nicotine dependence and their craving. Neuropsychobiology 50:78–88PubMed
Linnoila M, Virkkunen M, Scheinin M, Nuutila A, Rimon R, Goodwin FK (1983) Low cerebrospinal fluid 5-hydroxyindolacetic concentration differentiates impulsive from nonimpulsive violent behavoir. Life Sci 33:2609–2614PubMed
Litten RZ, Allen JP (1998) Advances in the development of medications for alcoholism treatment. Psychopharmacology 139:20–33PubMed
Longo LP, Campbell T, Hubatch S (2002) Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis 21(2):55–64PubMed
Lopez-Moreno JA, Gonzalez-Cuevas G, Navarro M (2007) The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol. Neurobiol Dis 25(2):274–283PubMed
Lotfullina N, Khazipov R (2018) Ethanol and the developing brain: inhibition of neuronal activity and neuroapoptosis. Neuroscientist 24(2):130–141PubMed
Lovinger DM (1997) Serotonin’s role in alcohol’s effect on the brain. Alcohol Health Res World 21(2):114–120PubMedPubMedCentral
Malcolm R, Anton RF, Randall CL, Johnston A, Brady K, Thevos A (1992) A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 16:1007–1013PubMed
Malec E, Malec T, Gagne MA, Dongier M (1996a) Buspirone in the treatment of alcohol dependence: a placebo.controlled trial. Alcohol Clin Exp Res 20:307–312PubMed
Malec TS, Malec EA, Dongier M (1996b) Efficacy of buspirone in alcohol dependence: a review. Alcohol Clin Exp Res 20:853–858PubMed
Mann K, Lehert P, Morgan MY (2004) The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 28(1):51–63PubMed
Mann K, Bladström A, Torup L, Gual A, van den Brinck W (2013) Extending the treatment options in alcohol dependence:a randomized controlled study o fas needed nalmefene. Biol Psychiatry 73:706–713PubMed
Marcinkiewcz CA, Lowery-Gionta EG, Kash TL (2016) Serotonin’s complex role in alcoholism: implications for treatment and future research. Alcohol Clin Exp Res 40(6):1192–1201PubMed
Markou A, Kosten TR, Koob GF (1998) Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18:135–174PubMed
Mason BJ (2015) Acamprosate, alcoholism, and abstinence. J Clin Psychiatry 76(2):e224–e225PubMed
Mason BJ, Kocsis JH, Ritvo EC, Cutler RB (1996) A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 13(275/10):761–767
Mason BJ, Quello S, Shadan F (2018) Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs 27(1):113–124PubMed
Mc Grath PJ, Nunes EV, Stewart JW, Goldman D, Agosti V, Ocepek-Welikson K, Quitkin FM (1996) Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry 53(3):232–240
McLaughlin I, Dani JA, De Biasi M (2015) Nicotine Withdrawal. Curr Top Behav Neurosci 24:99–123
Minozzi S, Saulle R, Rösner S (2018) Baclofen for alcohol use disorder. Cochrane Database Syst Rev 26:11
Miller WR, Rollnick S (2002) Motivational interviewing: Preparing people for change (2nd edition) Guilfort Press, New York
Mueller TI, Stout RL, Rudden S, Brown RA, Gordon A, Solomon DA, Recupero PR (1997) A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res 21(1):86–92PubMed
Murphy JK, Edwards NB, Downs AD, Ackerman BJ, Rosenthal TL (1990) Effects of doxepin on withdrawal symptoms in smoking cessation. Am J Psychiatry 147:1353–1357PubMed
Musshoff F, Lachenmeier DW, Schmidt P, Dettmeyer R, Madea B (2005) Systematic regional study of dopamine, norsalsolinol, and (R/S)-salsolinol levels in human brain areas of alcoholics. Alcohol Clin Exp Res 29(1):46–52PubMed
Nagy J (2004) Renaissance of NMDA receptor antagonists: do they have a role in the pharmacotherapy for alcoholism? Drugs 7(4):339–350
Nakamura-Palacios EM, de Almeida Benevides MC, da Penha Zago-Gomes M, de Oliveira RW, de Vasconcellos VF, de Castro LN, da Silva MC, Ramos PA, Fregni F (2012) Auditory event-related potentials (P3) and cognitive changes induced by frontal direct current stimulation in alcoholics according to Lesch alcoholism typology. Int J Neuropsychopharmacol 15(5):601–616PubMed
Naranjo CA, Knoke DM (2001) The role of selective serotonin reuptake inhibitors in reducing alcohol consumption. J Clin Psychiatry 62(20):18–25PubMed
National Institute for Clinical Excellence (2004) Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. National Institute for Clinical Excellence, London, Reference No. N0082
Nava F, Premi S, Manzato E, Lucchini A (2006) Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptions. J Psychoactive Drugs 38(3):211–217PubMed
Nguyen SA, Malcolm R, Middaugh LD (2007) Topiramate reduces ethanol consumption by C57BL/6 mice. Synapse 61(3):150–156PubMed
Nimmerrichter A, Walter H, Guttierez- Lobos K, Lesch OM (2002) Double – blind controlled trial of GHB and clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol 37(1):67–73PubMed
Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PR (2015) The dopamine theory of addiction: 40 years of highs and lows. Nat Rev Neurosci 16(5):305–312PubMed
O’Brien CP (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence. Curr Psychiatry Rep 7(5):327–328PubMed
O’Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D, Wu R, Makuch R, Jatlow P (2006) A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med 166(6):667–674PubMed
O’Malley SS, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, Rounsaville BJ, Wu R (2007) Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. Alcohol Clin Exp Res 31(4):625–634PubMed
Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K (2006) Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 166:1571–1577PubMed
Oncken C, Arias AJ, Feinn R, Litt M, Covault J, Sofuoglu M, Kranzler HR (2014) Topiramate for smoking cessation: a randomized, placebo-controlled pilot study. Nicotine Tob Res 16(3):288–296PubMed
Ooteman W, Koeter MW, Verheul R, Schippers GM, van den Brink W (2007) The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics. Eur Neuropsychopharmacol 17(8):558–566PubMed
Opalach C, Romaszko J, Jaracz M, Kuchta R, Borkowska A, Buciński A (2016) Coping styles and alcohol dependence among homeless people. PLoS One 11(9):e0162381PubMedPubMedCentral
Pakri Mohamed RM, Kumar J, Ahmad SU, Mohamed IN (2018) Noverl pharmacotherapeutic approaches in treatment of alcohol addiction. Curr Drug Targets 19(12):1378–1390PubMed
Palpacuer C, Duprez R, Huneau A, Locher C, Boussageon R, Laviolle B, Naudet F (2018) Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction 113(2):220–237. https://​doi.​org/​10.​1111/​add.​13974CrossRefPubMed
Paulus DJ, Manning K, Hogan JBD, Zvolensky MJ (2017) The role of anxiety sensitivity in the relation between anxious arousal and cannabis and alcohol use problems among low-income inner city racial/ethnic minorities. J Anxiety Disord 48:87–94PubMed
Petrakis IL, O’Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH, VA Naltrexone Study Collaboration Group (2004) Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology 172(3):291–297PubMed
Pettinati HM (2001) The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. J Clin Psychiatry 62(20):26–31PubMed
Pettinati HM (2004) Antidepressant treatment of co-occurring depression and alcohol dependence. Biol Psychiatry 56(10):785–792. ReviewPubMed
Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A (2000) Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 24:1041–1049PubMed
Pettinati HM, Kranzler HR, Madaras J (2003) The status of serotonin-selective pharmacotherapy in the treatment of alcohol dependence. Recent Dev Alcohol 16:247–262PubMed
Pettinati HM, O’Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA (2006) The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol 26(6):610–625PubMed
Pierce M, Sutterland A, Beraha E, Morley K, van den Brink W (2018) Efficacy, tolerability and safety of low dose and high dose baclofen in the treatment of alcohol dependence: a systematic review and meta analysis. Eur Neuropsychopharmacol 26:1959–1959
Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295(7):761–775PubMed
Pittman B, Gueorguieva R, Krupitsky E, Rudenko AA, Flannery BA, Krystal JH (2007) Multidimensionality of the alcohol withdrawal symptom checklist: a factor analysis of the alcohol withdrawal symptom checklist and CIWA-Ar. Alcohol Clin Exp Res 31(4):612–618PubMed
Pombo S, Luísa Figueira M, Walter H, Lesch O (2016) Motivational factors and negative affectivity as predictors of alcohol craving. Psychiatry Res 243:53–60PubMed
Prochaska J, DiClemente C (1992) Stages of change in modification of problem behaviors. In: Hersen M, Eisler R., Miller P (Eds) Progress in behavior modification, Sage, Newbury Park, CA, 84–218
Reddemann L (2014) Psychodynamisch Imaginative Traumatherapie: PITT – Das Manual. Ein resilienzorientierter Ansatz in der Psychotraumatologie. Leben lernen, Klett Cotta Stuttgart
Reid RD, Quinlan B, Riley DL, Pipe AL (2007) Smoking cessation: lessons learned from clinical trial evidence. Curr Opin Cardiol 22(4):280–285PubMed
Reynaud M, Aubin HJ, Trinquet F, Zakine B, Dano C, Dematteis M, Trojak B, Paille F, Detilleux M (2017) A randomized placebo- controlled study of high – dose baclofen in alcohol-dependent patients – The ALPADIR study. Alcohol Alcohol 52:439–446PubMed
Roberts W, Shi JM, Tetrault JM, McKee SA (2018) Effects of varenicline alone and in combination with low-dose naltrexone on alcohol-primed smoking in heavy-drinking tobacco users: a preliminary laboratory study. J Addict Med 12(3):227–233PubMedPubMedCentral
Robinson TE, Berridge KC (1993) The neural basis of drug craving-an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18:247–291PubMed
Rodda LN, Beyer J, Gerostamoulos D, Drummer OH (2013) Alcohol congener analysis and the source of alcohol: a review. Forensic Sci Med Pathol 9(2):194–207PubMed
Rohsenow DJ, Howland J (2010) The role of beverage congeners in hangover and other residual effects of alcohol intoxication: a review. Curr Drug Abuse Rev 3(2):76–79. ReviewPubMed
Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE (2007) Rationale, pharmacology and clinical efficacy of partial agonists of alpha(4)beta(2) nACh receptors for smoking cessation. Trends Pharamcol Sci 28(7):316–325
Rommelspacher H (2007) Rauchen aus der Sicht der Hirnforschung. In: Lesch OM (Hrsg) Raucherentwöhnung – Tipps zur Prävention und Therapie in der Praxis. Uni-Med Verlag, Wien
Rommelspacher H, May T, Dufeu P, Schmidt LG (1994) Longitudinal observations of monoamine oxidase B in alcoholics: differentiation of marker characteristics. Alcohol Clin Exp Res 18:1322–1329PubMed
Rose JE, Behm FM (2017) Combination varenicline/bupropion treatment benefits highly dependent smokers in an adaptive smoking cessation paradigm. Nicotine Tob Res 19(8):999–1002PubMed
Sällström Baum S, Hill R, Rommelspacher H (1995) Norharmaninduced changes of extracellular concentrations of dopamine in the nucleus accumbens of rats. Life Sci 56:1715–1720
Sällström Baum S, Hill R, Rommelspacher H (1996) Harman induced changes of extracellular concentrations of neurotransmitters in the nucleus accumbens of rats. Eur J Pharmacol 314:75–82
Samochowiec A, Chec M, Kopaczeweska E, Samochowiec J, Lesch O, Grochans E, Jasiewicz A, Bienkowski P, Lukasz K, Grzywacz A (2015) Monamine oxidase a promoter variable number of tandem repeats (MAOA-uVNTR ) in alcoholics according to Lesch typology. Int J Environ Res Public Health 12(3):3317–3327PubMedPubMedCentral
Scharf D, Shiffman S (2004) Are there gender differences in smoking cessation, with and without bupropion? Pooled-and meta-analyses of clinical trials of Bupropion SR. Addiction 99:1462–1469PubMed
Schnoll RA, Lerman C (2006) Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs 11(3):429–444PubMed
Schuckit M, SmithT, Pierson J, Danko G, Beltran IA (2006) Relationships among the level of response to alcohol and the number of alcoholic relatives in predicting alcohol-related outcomes. Alc Clin Exp Res 30 (8):11308–14
Scott-Goodwin AC, Puerto M, Moreno I (2016) Toxic effects of prenatal exposure to alcohol, tobacco and other drugs. Reprod Toxicol 61:120–130PubMed
Secades-Villa R, González-Roz A, García-Pérez Á, Becoña E (2017) Psychological, pharmacological, and combined smoking cessation interventions for smokers with current depression: a systematic review and meta-analysis. PLoS One 12(12):e0188849PubMedPubMedCentral
Shiffman S, Gnys M, Richards TJ, Paty JA, Hickcox M, Kassel JD (1996) Temptations to smoke after quitting: a comparison of lapsers and maintainers. Health Psychol 15:455–461PubMed
Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, Gnys M, Evoniuk G, DeVeaugh-Geiss J (2000) The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology 148:33–40PubMed
Shoaib M, Buhidma Y (2018) Why are Antidepressant Drugs Effective Smoking Cessation Aids? Curr Neuropharmacol 16:426–437
Simiand J, Keane M, KeanePE SP (1998) SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9(2):179–181PubMed
Simon JA, Duncan C, Carmody TP, Hudes ES (2004) Bupropion for smoking cessation: a randomized trial. Arch Intern Med 164(16):1797–1803PubMed
Sinclair JD (2001) Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol 36(1):2–10PubMed
Skala K, Caputo F, Mirijello A, Vassallo G, Antonelli M, Ferrulli A, Walter H, Lesch O, Addolorato G (2014) Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. Expert Opin Pharmacother 15(2):245–257; ReviewPubMed
Soyka M, Müller CA (2017) Pharmacotherapy of alcoholism – an update on approved and off-label medications. Expert Opin Pharmacother 18(12):1187–1199PubMed
Soyka M, Koller G, Schmidt P, Lesch OM, Leweke M, Fehr C, Gann H, Mann KF, ACTOL Study Investigators (2008) Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol 28(3):317–324PubMed
Soyka M, Friede M, Schnitker J (2016) Comparing nalmefene and naltrexone in alcohol dependence: are there any differences? Results from an indirect meta – analysis. Pharmacopsychiatry 49(2):66–75PubMed
Spanagel R, Hölter SM (1999) Long-term-alcohol self-administration with repeated alcohol deprivation phases; an animal model of alcoholism? Alcohol Alcohol 34(2):231–243PubMed
Spanagel R, Zieglgansberger W (1997) Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 18(2):54–59PubMed
Sprung R, Bonte W, Lesch OM (1988) Methanol, Ein bisher verkannter Bestandteil aller alkoholischen Getränke; Eine neue biochemische Annäherung an das Problem des chronischen Alkoholismus. Wien Klin Wochenschr 100(9):282–288PubMed
Starosta AM, Leeman R, Volpicelli MD (2006) The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiatr Pract 12:80–89PubMedPubMedCentral
Stead L, Lancaster T (2007) Interventions to reduce harm from continued tobacco use. Cochrane Database Syst Rev 18(3):CD005231
Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE (2007) Varenicline, an {alpha}4{beta}2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A 104(30):12518–12523PubMedPubMedCentral
Stolz D, Scherr A, Seiffert B, Kuster M, Meyer A, Fagerström KO, Tamm M (2014) Predictors of success for smoking cessation at the workingplace: a longitudinal study. Respiration 87:18–25PubMed
Stuppaeck CH, Barnas C, Falk M, Guenther V, Hummer M, Oberbauer H, Pycha R, Whitworth AB, Fleischhacker WW (1994) Assessment of the alcohol withdrawal syndrome-validity and reliability of the translated and modified Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-A). Addiction 89(10):1287–1292PubMed
Sullivan EV, Pfefferbaum A (2005) Neurocircuitry in alcoholism: a substrate of disruption and repair. Psychopharmacology 180(4):583–594PubMed
Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. (1989) Assessment of alcohol withdrawal: The revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar). British J of Addiction 84:1353–1357
Sullivan J, Baenziger JC, Wagner DL, Rauscher FP, Nurnberger JI, Holmes S (1990) Platelet MAO in subtypes of alcoholism. Biol Psychiatry 27:911–922PubMed
Swann AS, Johnson BA, Cloninger CR, Chen YR (1999) Alcoholism and serotonin: relationships of plasma tryptophan availibility to course of illness and clinical features. Psychopharmacology 143:380–384PubMed
Sweeney CT, Fant RV, Fagerström KO, McGovern JF, Henningfield JE (2001) Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs 15:453–467PubMed
Tabakoff B, Hoffmann PL (1991) Neurochemical effects of alcohol. In: Frances RJ, Miller SI (Hrsg) Clinical textbook of addictive disorders. Guilford Press, New York, S 501–525
Taylor GMJ, Taylor AE, Thomas KH, Jones T, Martin RM, Munafò MR, Windmeijer F, Davies NM (2017) The effectiveness of varenicline versus nicotine replacement therapy on long-term smoking cessation in primary care: a prospective cohort study of electronic medical records. Int J Epidemiol 46(6):1948–1957PubMedPubMedCentral
Tellenbach H (1983) Melancholie, 4. Aufl. Springer, Berlin/Göttingen/Heidelberg
Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, Rijcken B, SaweU (1999) Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J 13:238–246PubMed
Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR (2006) Effect of maintenance therapy with varenicline on smoking cessation – a randomized controlled trial. JAMA 296(1):64–71PubMed
UNODC, WHO (2016) Commission on narcotic drugs, international standards for the treatment of drug use
US Department of Health and Human Services (2000) Management of nicotine addiction. reducing tobacco use: a report of the surgeon general. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta
Van den Brink W, Sorensen P, Torup L, Mann K, Gual A, SENSE Study Group (2014) Long – term efficacy, tolerability and safety of nalmefene as- needed in patients with alcohol dependence: a 1 year, randomized controlled study. J Psychopharmacol 28:733–744PubMed
Van Praag HM, Brown SL, Asnis GM, Kahn RS, Korn ML, Harkavy-Friedman JM, Wetzler S (1991) Beyond serotonin: a multiaminergic perspective on abnormal behavior. In: Brown SL, van Praag HM (Hrsg) The role of serotonin in psychiatric disorders. Brunner/Mazel, New York, S 302–332
Vengeliene V, Olevska A, Spanagel R (2015) Long-lasting effect of NMDA receptor antagonist memantine on ethanol-cue association and relapse. J Neurochem 135(6):1080–1085PubMed
Verheul R, Lehert P, Geerlings PJ, Koeter MW, van den Brink W (2005) Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcoholdependent patients. Psychopharmacology 178(2–3):167–173PubMed
Virkkunen M, Linnoila M (1997) Serotonin on early-onset alcoholism. Recent Dev Alcohol 13:173–189PubMed
Virkkunen M, Rawlings R, Tokola R, Poland RE, Guidotti A, Nemeroff C, Bissette G, Kalogeras K, Karonen SL, Linnoila M (1994) CSF biochemistries, glucose metabolism, and diurnal a ctivity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry 51:20–27PubMed
Virkkunen M, Eggert M, Rawlings R, Linnoila M (1996) A prospective follow-up study of alcoholic violent offenders and fire setters. Arch Gen Psychiatry 53:523–529PubMed
Volkow N, Koob G, McLellan T (2016) Neurobiologic advances from the brain disease model of addiction. N Engl J Med 374:4
Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49(11):876–880PubMed
Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O’Brien CP (1997) Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 54(8):737–742PubMed
Vyssoki B, Steindl-Munda P, Ferenci P, Walter H, Höfer P, Blüml V, Friedrich F, Kogoj D, Lesch OM (2010) Comparison of alcohol-dependent patients at a gastroenterological and a psychiatric ward according to the Lesch alcoholism typology: implications for treatment. Alcohol Alcohol 45(6):534–540PubMed
Walter H (2015) Alkohol. In: Revenstorf D, Peter B (Hrsg) Hypnose in Psychotherapie, Psychosomatik und Medizin. Manual für die Praxis. Kapitel 28, 3. Aufl. Springer, Heidelberg
Walter H, Ramskogler K, Semler B, Lesch OM, Platz W (2001) Dopamine and alcohol relapse: D1 and D2 antagonists increase relapse rates in animal studies and in clinical trials. J Biomed Sci 8:83–88PubMed
Wang J, Rao Y, Houser DE (2017) An experimental analysis of acquired impulsecontrol among adult humans intolerant to alcohol. Proc Natl Acad Sci U S A 114(6):1299–1304PubMedPubMedCentral
Weinshenker D, Schroeder JP (2007) There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacology 32(7):1433–1451PubMed
Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker WW (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347(9013):1438–1442PubMed
Widiger TA, Frances AJ, Picus HA, First MB, Ross R, Davis W (1994) DSM-IV sourcebook, Bd 1. American Psychiatric Association, Washington DC
Wieck HH (1967) Lehrbuch für Psychiatrie. Schattauer, Stuttgart
Wiener CD, Moreira FP, Zago A, Souza LM, Branco JC, Oliveira JF, Silva RAD, Portela LV, Lara DR, Jansen K, Oses JP (2018) Mood disorder, anxiety, and suicide risk among subjects with alcohol abuse and/or dependence: a population-based study. Braz J Psychiatry 40(1):1–5PubMed
Wiesbeck GA, Weijers HG, Lesch OM, Glaser T, Toennes PJ, Boening J (2001) Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol Alcohol 36(4):329–334PubMed
Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J (2007) A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 23(4):793–801PubMed
World Health Organization (2003) Policy recommendations for smoking cessation and treatment of tobacco dependence. World Health Organization, Geneva
Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, Bernstein Y, Thomas KJ, Kim E, Walker JM, Nagar S, Ward SJ, Raffa RB (2007) The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use. J Clin Pharm Ther 32(3):209–231PubMed
Yates GL, MacKenzie R, Pennbridge J, Cohen E (1988) A risk profile comparison of runaway and non-runaway youth. Am J Public Health 78:820–821PubMedPubMedCentral
Yuanyuan J, Junyan Z, Cuola D, Jingjing C, Yuhui S, Dan X, Wei D, Yongsheng Z (2018) Memantine attenuated alcohol withdrawal-induced anxiety-like behaviors through down-regulating NR1-CaMKII-ERK signaling pathway. Neurosci Lett 686:133–139PubMed
Zago-Gomes Mda P, Nakamura-Palacios EM (2009) Cognitive components of frontal lobe function in alcoholics classified according to Lesch’s typology. Alcohol Alcohol 44:449PubMed
Zierler-Brown S, Kyle JA (2007) Oral varenicline for smoking cessation. Ann Pharmacother 41:95–99PubMed
Metadaten
Titel
Therapeutische Strategien bei Alkohol- und Tabakabhängigkeit
verfasst von
Otto-Michael Lesch
Henriette Walter
Samuel Pombo
Victor Hesselbrock
Michie Hesselbrock
Copyright-Jahr
2020
Verlag
Springer Berlin Heidelberg
Buch
Alkohol und Tabak

Print ISBN: 978-3-662-60283-6

Electronic ISBN: 978-3-662-60284-3

Copyright-Jahr: 2020

DOI
https://doi.org/10.1007/978-3-662-60284-3_9

Neu im Fachgebiet Psychiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Bildnachweise